Aprogen Medicines Inc. (007460.KS)
KRW 816.0
(-3.09%)
KRW 816.0
(-3.09%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -235.50 KRW | 86.39% |
| 2022 | -1730.97 KRW | -791.7% |
| 2021 | -194.12 KRW | 66.4% |
| 2020 | -577.78 KRW | -243.69% |
| 2019 | 402.11 KRW | 121.21% |
| 2018 | -1895.62 KRW | -640.17% |
| 2017 | 350.93 KRW | -20.41% |
| 2016 | 440.91 KRW | -48.96% |
| 2015 | 863.83 KRW | -75.86% |
| 2014 | 3578.28 KRW | 120.85% |
| 2013 | -17.16 Thousand KRW | -126.34% |
| 2012 | -7584.13 KRW | 80.93% |
| 2011 | -39.77 Thousand KRW | -285.14% |
| 2010 | -10.32 Thousand KRW | -400.0% |
| 2009 | 3442.29 KRW | -57.35% |
| 2008 | 8071.58 KRW | 2.99% |
| 2007 | 7836.96 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -11.47 KRW | 90.6% |
| 2024 Q1 | -121.96 KRW | -271.9% |
| 2023 Q2 | -61.09 KRW | 19.86% |
| 2023 Q1 | -76.23 KRW | 80.3% |
| 2023 Q3 | -141.52 KRW | -131.66% |
| 2023 FY | - KRW | 86.39% |
| 2023 Q4 | 70.95 KRW | 150.13% |
| 2022 Q3 | -93.60 KRW | 17.3% |
| 2022 FY | - KRW | -791.7% |
| 2022 Q1 | 2.60 KRW | 103.59% |
| 2022 Q2 | -113.18 KRW | -4453.08% |
| 2022 Q4 | -386.98 KRW | -313.44% |
| 2021 Q3 | -140.97 KRW | 22.95% |
| 2021 Q4 | -72.50 KRW | 48.57% |
| 2021 FY | - KRW | 66.4% |
| 2021 Q1 | -134.97 KRW | -33.28% |
| 2021 Q2 | -182.96 KRW | -35.56% |
| 2020 Q1 | -236.95 KRW | -41.53% |
| 2020 Q2 | -788.84 KRW | -232.91% |
| 2020 Q3 | 497.90 KRW | 163.12% |
| 2020 Q4 | -101.27 KRW | -120.34% |
| 2020 FY | - KRW | -243.69% |
| 2019 Q2 | 176.96 KRW | 481.21% |
| 2019 FY | - KRW | 121.21% |
| 2019 Q1 | -46.42 KRW | 86.42% |
| 2019 Q4 | -167.42 KRW | -184.57% |
| 2019 Q3 | 197.96 KRW | 11.87% |
| 2018 Q1 | -51.57 KRW | 0.0% |
| 2018 Q4 | -341.83 KRW | -0.86% |
| 2018 FY | - KRW | -640.17% |
| 2018 Q3 | -338.93 KRW | 18.12% |
| 2018 Q2 | -413.92 KRW | -702.64% |
| 2017 Q1 | 155.97 KRW | 1514.6% |
| 2017 Q3 | 12.00 KRW | -80.0% |
| 2017 FY | - KRW | -20.41% |
| 2017 Q2 | 59.99 KRW | -61.54% |
| 2016 FY | - KRW | -48.96% |
| 2016 Q2 | 164.97 KRW | -60.99% |
| 2016 Q1 | 422.92 KRW | 592.23% |
| 2016 Q3 | -161.97 KRW | -198.18% |
| 2016 Q4 | 9.66 KRW | 105.96% |
| 2015 FY | - KRW | -75.86% |
| 2015 Q4 | -85.92 KRW | -134.62% |
| 2015 Q3 | 248.19 KRW | -47.3% |
| 2015 Q2 | 470.91 KRW | -13.74% |
| 2015 Q1 | 545.89 KRW | 3.85% |
| 2014 Q3 | 256.08 KRW | -50.07% |
| 2014 Q2 | 512.90 KRW | -58.39% |
| 2014 Q1 | 1232.75 KRW | 444.34% |
| 2014 FY | - KRW | 120.85% |
| 2014 Q4 | 525.63 KRW | 105.26% |
| 2013 Q3 | 169.85 KRW | 102.85% |
| 2013 Q1 | -829.51 KRW | 58.33% |
| 2013 Q4 | -358.00 KRW | -310.77% |
| 2013 FY | - KRW | -126.34% |
| 2013 Q2 | -5955.40 KRW | -617.94% |
| 2012 FY | - KRW | 80.93% |
| 2012 Q1 | 783.42 KRW | 104.92% |
| 2012 Q2 | 27.45 Thousand KRW | 3404.38% |
| 2012 Q3 | -14.7 Thousand KRW | -153.58% |
| 2012 Q4 | -1990.44 KRW | 86.47% |
| 2011 Q4 | -15.92 Thousand KRW | -1653.15% |
| 2011 FY | - KRW | -285.14% |
| 2011 Q1 | 1614.32 KRW | 174.3% |
| 2011 Q2 | -17.94 Thousand KRW | -1211.47% |
| 2011 Q3 | -908.35 KRW | 94.94% |
| 2010 Q3 | -1412.53 KRW | 58.68% |
| 2010 Q4 | -2172.64 KRW | -53.81% |
| 2010 Q2 | -3418.55 KRW | -423.59% |
| 2010 Q1 | 1056.43 KRW | 293.44% |
| 2010 FY | - KRW | -400.0% |
| 2009 Q3 | 1175.13 KRW | -46.49% |
| 2009 Q4 | -546.13 KRW | -146.47% |
| 2009 Q2 | 2195.95 KRW | 28.47% |
| 2009 Q1 | 1709.28 KRW | 349.91% |
| 2009 FY | - KRW | -57.35% |
| 2008 Q1 | 3969.75 KRW | 823.82% |
| 2008 Q2 | 2397.73 KRW | -39.6% |
| 2008 Q3 | 1258.22 KRW | -47.52% |
| 2008 Q4 | 379.92 KRW | -69.8% |
| 2008 FY | - KRW | 2.99% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q3 | 2125.11 KRW | -22.91% |
| 2007 Q4 | 429.71 KRW | -79.78% |
| 2007 Q2 | 2756.52 KRW | -0.49% |
| 2007 Q1 | 2770.05 KRW | 0.0% |